PD13: Bladder Cancer: Non-invasive II

Podium Session Moderator(s)

• 

  John Gore, MD,MS

  University of Washington
• 

  Kamal Pohar, MD (he/him/his)

  The Ohio State University

Presentations:

• 7:00 AM – 7:10 AM CST

  PD13-01: Cost-effectiveness of Initial Management of High-grade T1 Bladder Cancer with Intravesical BCG vs Immediate Radical Cystectomy
  

  Podium Presenter: Facundo M. Davaro, MD
• 7:10 AM – 7:20 AM CST

  PD13-02: Can Experience of Blue Light Cystoscopy Improve a Surgeon's White Light Resection? Data from the PHOTO trial.
  

  Podium Presenter: Rakesh Heer
• 7:20 AM – 7:30 AM CST

  PD13-03: A cystoscopy artificial intelligence system that can be used with cystoscopes produced by different manufacturers
  

  Podium Presenter: Atsushi Ikeda, MD,PhD – University of Tsukuba
• 7:30 AM – 7:40 AM CST

  PD13-04: Development of a Novel Gene Expression Scoring System for Recurrence in Non-muscle-invasive Bladder Cancer after Transurethral Resection of Bladder Tumor
  

  Podium Presenter: Emina Kayama, MD
• 7:40 AM – 7:50 AM CST

  PD13-05: Long-term oncological outcomes of office-based fulguration of Ta low-grade non muscle invasive bladder cancer: a large single center series
  

  Podium Presenter: Alexandre R. Zlotta, MD,PhD – Mount Sinai Hospital
• 7:50 AM – 8:00 AM CST

  PD13-06: Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
  

  Podium Presenter: Yun-sok Ha – Chungbuk National University Hospital
• 8:00 AM – 8:10 AM CST

  PD13-07: Multiparametric MRI of the bladder as a predictive factor of histopathology at reTUR in T1GH with presence of detrusor muscle: could it have a role?
  

  Podium Presenter: Andrea Giordano, MD
• 8:10 AM – 8:20 AM CST

  PD13-08: CORE1: Phase 2 Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (BCG)
  

  Podium Presenter: Roger Li, MD – H. Lee Moffitt Cancer Center
• 8:20 AM – 8:30 AM CST

  PD13-09: Clinical validation of the EAU2021 intermediate risk NMIBC definition and implications for adjuvant treatment: a multicenter YAU Urothelial Collaboration
  

  Podium Presenter: PAOLO GONTERO, MD
• 8:30 AM – 8:40 AM CST

  PD13-10: The impact of purified protein derivative prior to intravesical bacillus Calmette-Guérin for the treatment of patients with non-muscle invasive bladder cancer: A controlled clinical trial
  

  Podium Presenter: Mohamed Zawky
• 8:40 AM – 8:50 AM CST

  PD13-11: Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumor: A Multi-Center Randomized Trial (EB-StaR Study)
  

  Podium Presenter: Jeremy Teoh, MD (he/him/his) – Prince of Wales Hospital
• 8:50 AM – 9:00 AM CST

  PD13-12: Bladder sparing treatment in patients with BCG unresponsive non-muscle invasive bladder cancer: An analysis of long-term survival outcomes
  

  Podium Presenter: Wei Shen Tan
• 9:00 AM – 9:10 AM CST

  PD13-13: A Fully Automated Artificial Intelligence Support System for Urine Cytology: Multi-Center External Validation Study
  

  Podium Presenter: Masatomo Kaneko, MD, PhD (he/him/his)
• 9:10 AM – 9:20 AM CST

  PD13-14: The genetic information of non-muscle invasive bladder cancer associated with recurrence
  

  Podium Presenter: Seong Hyeon Yu